Randomized Trial to Test the Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 19
- 试验地点
- 2
- 主要终点
- PBAC Scores
研究概览
简要总结
A large proportion of women with menstruating potential with newly diagnosed VTE or atrial fibrillation, treated with apixaban will have less menstrual blood loss than patients randomized to rivaroxaban.
详细描述
Heavy menstrual bleeding (HMB) complicates the treatment of approximately 9-25% of patients treated with orally administered anti-Xa anticoagulants for venous thromboembolism (VTE, including either pulmonary embolism or deep vein thrombosis). In particular, recent evidence has suggested an increase in length and severity of menstrual bleeding for women treated with rivaroxaban, and this effect may be less severe apixaban treatment.(1;2) Increase in uterine bleeding with rivaroxaban has necessitated hysterectomy in rare cases.(3) Other complications of HMB include reduced drug adherence, decreased perception of wellness (quality of life) and anemia.(4;5) The anti-Xa agents may increase HMB more than vitamin K antagonists.(1) However, in the principal investigators' experience treating over 100 women of menstruating age with rivaroxaban for VTE with varying degree of HMB, no woman has expressed desire to switch to a VKA even when offered this option (unpublished data). We have successfully reduced perception of HMB by switching from rivaroxaban to apixaban in six patients. Comparison of published and supplemental data from AMPLIFY and AMPLIFY Extend to EINSTEIN and EINSTEIN extend trials also support a lower rate of uterine bleeding with apixaban compared with rivaroxaban, although exact comparisons are difficult to make.(6;9) Myers et al recently reported a 9.4% rate of HMB with apixaban, compared with a 25% rate of HMB with rivaroxaban.(2) Accordingly, we hypothesize that women with menstruating potential with newly diagnosed VTE or atrial fibrillation/flutter, treated with apixaban will have less menstrual blood loss than patients randomized to rivaroxaban.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Non-pregnant women, age 18-50
- •For study purposes, evidence of negative pregnancy is accounted for by the treating physician's initiation of treatment with oral anticoagulants
- •Objectively diagnosed VTE or atrial fibrillation/flutter
- •Patient reported active menstruation - does not apply to women who were recently pregnant
- •Clinical plan and patient agreement to treat with oral anticoagulation for 3 months or longer
- •Patients must have a working telephone
排除标准
- •Package insert exclusions for Eliquis (Apixban) or Xarelto (Rivaroxaban): [active pathological bleeding or severe hypersensitivity reaction to XARELTO or ELIQUIS (e.g., anaphylactic reactions)]
- •Plan to become pregnant in the next three months.
- •Concomitant prescribed use of aspirin or thienopyridenes or other platelet inhibiting drugs
- •Plan for surgical hysterectomy or endometrial ablation
- •Known uterine cancer
- •Von Willebrand's disease, or hemophilia
- •Known coagulopathy from liver disease
- •Conditions likely to preclude adherence to study procedures: Active intravenous drug use, known alcoholism, homelessness, or uncontrolled psychiatric illness.
研究组 & 干预措施
Rivaroxaban
干预措施: Rivaroxaban (Drug)
Apixaban
干预措施: Apixaban (Drug)
结局指标
主要结局
PBAC Scores
时间窗: 3 months
Measure Description: A PBAC Score of \< 100 indicates a normal menstrual cycle. The lowest possible score would be zero. Higher values indicate worse outcomes. The higher theoretical range value cannot be calculated. The scoring mechanism is as follows; Towels * 1 point for each lightly stained towel * 5 points or each moderately soiled towel * 20 points if the towel is completely saturated with blood Tampons * 1 point for each lightly stained tampon * 5 points for each moderately soiled tampon * 10 points if the tampon is completely saturated with blood Clots * 1 point for small clots * 5 points for large clots
次要结局
- Number of Participants Who Discontinued Planned Drug Administration(3 months)
- Number of Patients That Held Drug for Menorrhagia(1, 2, and 3 months)
- Number of Participants With Major Hemorrhage(3 months)
- Number of Participants With Venous Thromboembolism (VTE)(3 months)
- Number of Participants Who Crossed Over to Another Anticoagulant(3 months)
- Number of Participants With Clinically Relevant Non-major Bleeding(3 months)
- Hemoglobin Concentration(3 months)
- Physical Component Summary of Standard From 36(3 months)
研究者
Jeffrey Kline
Principal Investigator
Indiana University